BNN BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.…
Industry Peers
Specialty ChemicalsKey Statistics
About BRAIN Biotech (ETR: BNN)
›
BRAIN Biotech (ETR: BNN) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 280 employees.
The shares were at 2.510 EUR on 19 November 2026, down 11.0% over 52 weeks. Its 52-week range is 2.130 EUR to 3.740 EUR: the price is 32.9% below the high and 17.8% above the low.
Its market capitalisation is 54.84M EUR.
BRAIN Biotech reports an operating margin of -18.3% and revenue down 16.5% year over year.
It holds more cash than debt, a net cash position of 940.00K EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 5.750 EUR is 129.1% above the current price.